New horizons for multiple sclerosis therapeutics: milestones in the development of ocrelizumab

Multiple Sclerosis (MS) is an inflammatory and neurodegenerative disease of the central nervous system, and both T and B cells are involved in its pathogenesis. The vast majority of disease-modifying drugs used for MS act on the inflammatory component of the disease and are approved for use in relap...

Descripción completa

Detalles Bibliográficos
Autores principales: Frau, Jessica, Coghe, Giancarlo, Lorefice, Lorena, Fenu, Giuseppe, Cocco, Eleonora
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5922247/
https://www.ncbi.nlm.nih.gov/pubmed/29719400
http://dx.doi.org/10.2147/NDT.S147874

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5922247/
https://www.ncbi.nlm.nih.gov/pubmed/29719400
http://dx.doi.org/10.2147/NDT.S147874

Ejemplares similares